199 related articles for article (PubMed ID: 19261633)
1. Widespread mismatch repair protein expression in canine cutaneous mast cell tumors.
Munday JS; French AF; Gibson IR; Gwynne K
Vet Pathol; 2009 Mar; 46(2):227-32. PubMed ID: 19261633
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair protein expression in ovine intestinal adenocarcinomas.
Munday JS; Frizelle FA; Whitehead MR
Vet Pathol; 2008 Jan; 45(1):3-6. PubMed ID: 18192567
[TBL] [Abstract][Full Text] [Related]
3. Widespread mismatch repair expression in feline small intestinal lymphomas.
Aberdein D; Munday JS; Howe L; French AF; Gibson IR
J Comp Pathol; 2012 Jul; 147(1):24-30. PubMed ID: 22000951
[TBL] [Abstract][Full Text] [Related]
4. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
[TBL] [Abstract][Full Text] [Related]
5. An immunohistochemical study of vitamin D receptor expression in canine cutaneous mast cell tumours.
Russell DS; Rassnick KM; Erb HN; Vaughan MM; McDonough SP
J Comp Pathol; 2010; 143(2-3):223-6. PubMed ID: 20334872
[TBL] [Abstract][Full Text] [Related]
6. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
Meyer A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
[TBL] [Abstract][Full Text] [Related]
7. Expression of Ki67, BCL-2, and COX-2 in canine cutaneous mast cell tumors: association with grading and prognosis.
Vascellari M; Giantin M; Capello K; Carminato A; Morello EM; Vercelli A; Granato A; Buracco P; Dacasto M; Mutinelli F
Vet Pathol; 2013 Jan; 50(1):110-21. PubMed ID: 22673539
[TBL] [Abstract][Full Text] [Related]
8. TSLC1 tumour-suppressor gene expression in canine mast cell tumours.
Taylor F; Murphy S; Hoather T; Dobson J; Scase T
Vet Comp Oncol; 2010 Dec; 8(4):263-72. PubMed ID: 21062408
[TBL] [Abstract][Full Text] [Related]
9. Differences in the proteome of high-grade versus low-grade canine cutaneous mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Einspanier R; Gruber AD; Klopfleisch R
Vet J; 2012 Nov; 194(2):210-4. PubMed ID: 22578690
[TBL] [Abstract][Full Text] [Related]
10. Glucocorticoid sensitivity depends on expression levels of glucocorticoid receptors in canine neoplastic mast cells.
Matsuda A; Tanaka A; Amagai Y; Ohmori K; Nishikawa S; Xia Y; Karasawa K; Okamoto N; Oida K; Jang H; Matsuda H
Vet Immunol Immunopathol; 2011 Dec; 144(3-4):321-8. PubMed ID: 21908058
[TBL] [Abstract][Full Text] [Related]
11. Association of Ki67 index with prognosis for intermediate-grade canine cutaneous mast cell tumours.
Maglennon GA; Murphy S; Adams V; Miller J; Smith K; Blunden A; Scase TJ
Vet Comp Oncol; 2008 Dec; 6(4):268-74. PubMed ID: 19178685
[TBL] [Abstract][Full Text] [Related]
12. Comparison of serum tryptase as a diagnostic oncological marker in canine versus human mast cell neoplasms.
De Vos S; Demeyere K; De Cock H; Devriendt N; Schwarzkopf I; Fortrie R; Roggeman T; Meyer E; De Spiegelaere W; de Rooster H
Res Vet Sci; 2022 Dec; 151():90-95. PubMed ID: 35872552
[TBL] [Abstract][Full Text] [Related]
13. Impact of tumour depth, tumour location and multiple synchronous masses on the prognosis of canine cutaneous mast cell tumours.
Kiupel M; Webster JD; Miller RA; Kaneene JB
J Vet Med A Physiol Pathol Clin Med; 2005 Aug; 52(6):280-6. PubMed ID: 16050909
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical Expression of the Pluripotency Factor OCT4 in Canine Mast Cell Tumours.
Vargas TH; Pulz LH; Barra CN; Kleeb SR; Xavier JG; Catão-Dias JL; Fukumasu H; Nishiya AT; Strefezzi RF
J Comp Pathol; 2015 Nov; 153(4):251-5. PubMed ID: 26460092
[TBL] [Abstract][Full Text] [Related]
15. c-KIT messenger RNA and protein expression and mutations in canine cutaneous mast cell tumors: correlations with post-surgical prognosis.
Giantin M; Vascellari M; Morello EM; Capello K; Vercelli A; Granato A; Lopparelli RM; Nassuato C; Carminato A; Martano M; Mutinelli F; Dacasto M
J Vet Diagn Invest; 2012 Jan; 24(1):116-26. PubMed ID: 22362941
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical evaluation of prostaglandin E2 and vascular endothelial growth factor in canine cutaneous mast cell tumours.
Amorim RL; Pinczowski P; Neto RT; Rahal SC
Vet Comp Oncol; 2010 Mar; 8(1):23-7. PubMed ID: 20230578
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical application of an antibody specific for human CD1a to the diagnosis of canine mast cell tumour.
Yhee JY; Hong SW; Yu CH; Doster AR; Blas-Machado U; Lyoo YS; Sur JH
J Comp Pathol; 2008 Jul; 139(1):40-6. PubMed ID: 18602642
[TBL] [Abstract][Full Text] [Related]
18. Expression of proto-oncogene C-kit and correlation with morphological evaluations in canine cutaneous mast cell tumors.
Passantino L; Passantino G; Cianciotta A; Ribaud MR; Lo Presti G; Ranieri G; Perillo A
Immunopharmacol Immunotoxicol; 2008; 30(3):609-21. PubMed ID: 18608529
[TBL] [Abstract][Full Text] [Related]
19. Expression of serotonin and its 5-HT1A receptor in canine cutaneous mast cell tumours.
Fröberg GK; Lindberg R; Ritter M; Nordlind K
J Comp Pathol; 2009; 141(2-3):89-97. PubMed ID: 19446835
[TBL] [Abstract][Full Text] [Related]
20. CD25 is expressed by canine cutaneous mast cell tumors but not by cutaneous connective tissue mast cells.
Meyer A; Gruber AD; Klopfleisch R
Vet Pathol; 2012 Nov; 49(6):988-97. PubMed ID: 22446323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
